Epidemiologic and Economic Analysis of Rapid Antiretroviral Therapy Initiation with Bictegravir/Emtricitabine/Tenofovir Alafenamide in Spain
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Epidemiologic and Economic Analysis of Rapid Antiretroviral Therapy Initiation with Bictegravir/Emtricitabine/Tenofovir Alafenamide in Spain
Authors
Keywords
-
Journal
Pharmacoeconomics-Open
Volume -, Issue -, Pages -
Publisher
Springer Science and Business Media LLC
Online
2022-02-06
DOI
10.1007/s41669-022-00322-w
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- 2019 update of the European AIDS Clinical Society Guidelines for treatment of people living with HIV version 10.0
- (2020) L Ryom et al. HIV MEDICINE
- Global, regional, and national incidence, prevalence, and mortality of HIV, 1980–2017, and forecasts to 2030, for 195 countries and territories: a systematic analysis for the Global Burden of Diseases, Injuries, and Risk Factors Study 2017
- (2019) Tahvi D Frank et al. Lancet HIV
- Serious Non-AIDS Conditions in HIV: Benefit of Early ART
- (2018) Jens D. Lundgren et al. Current HIV/AIDS Reports
- Economic Impact of HIV in the Highly Active Antiretroviral Therapy Era - Reflections Looking Forward
- (2018) Juan Oliva-Moreno et al. AIDS REVIEWS
- Bictegravir/Emtricitabine/Tenofovir Alafenamide: A Review in HIV-1 Infection
- (2018) Emma D. Deeks DRUGS
- Economic and epidemiologic impact of guidelines for early ART initiation irrespective of CD4 count in Spain
- (2018) Parastu Kasaie et al. PLoS One
- Risk of HIV transmission during combined ART initiation for HIV-infected persons with severe immunosuppression
- (2017) V Supervie et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Current status of HIV/AIDS in the ART era
- (2017) Kazuhisa Yoshimura JOURNAL OF INFECTION AND CHEMOTHERAPY
- Coformulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection (GS-US-380–1490): a randomised, double-blind, multicentre, phase 3, non-inferiority trial
- (2017) Paul E Sax et al. LANCET
- Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial
- (2017) Joel Gallant et al. LANCET
- Raltegravir 1200 mg once daily versus raltegravir 400 mg twice daily, with tenofovir disoproxil fumarate and emtricitabine, for previously untreated HIV-1 infection: a randomised, double-blind, parallel-group, phase 3, non-inferiority trial
- (2017) Pedro Cahn et al. Lancet HIV
- High variability of HIV and HCV seroprevalence and risk behaviours among people who inject drugs: results from a cross-sectional study using respondent-driven sampling in eight German cities (2011–14)
- (2016) Benjamin Wenz et al. BMC PUBLIC HEALTH
- Barreras para el inicio del tratamiento antirretroviral en pacientes con virus de la inmunodeficiencia humana e indicación de tratamiento en España. ¿Por qué no inician tratamiento quienes lo tienen indicado? Estudio Bridgap
- (2015) Pompeyo Viciana-Fernández et al. ENFERMEDADES INFECCIOSAS Y MICROBIOLOGIA CLINICA
- Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials
- (2015) Paul E Sax et al. LANCET
- Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection
- (2015) NEW ENGLAND JOURNAL OF MEDICINE
- Mortality, Causes of Death and Associated Factors Relate to a Large HIV Population-Based Cohort
- (2015) César Garriga et al. PLoS One
- Week 48 results from a randomized clinical trial of rilpivirine/emtricitabine/tenofovir disoproxil fumarate vs. efavirenz/emtricitabine/tenofovir disoproxil fumarate in treatment-naive HIV-1-infected adults
- (2014) Calvin Cohen et al. AIDS
- Dolutegravir plus Abacavir–Lamivudine for the Treatment of HIV-1 Infection
- (2013) Sharon L. Walmsley et al. NEW ENGLAND JOURNAL OF MEDICINE
- Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeks
- (2012) Paul E Sax et al. LANCET
- Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3, non-inferiority trial
- (2012) Edwin DeJesus et al. LANCET
- Characteristics of and outcomes in HIV-infected patients who return to care after loss to follow-up
- (2009) Bakhao Ndiaye et al. AIDS
- The cost-effectiveness of Vancouver's supervised injection facility
- (2008) A. M. Bayoumi et al. CANADIAN MEDICAL ASSOCIATION JOURNAL
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started